Gary Waanders
Investor Relations Contact bij AC IMMUNE SA
Profiel
Gary Waanders is currently the Head-Investor Relations & Corporate Communications at AC Immune SA. Previously, he worked as the Managing Director at Bryan, Garnier & Co Ltd.
from 2017 to 2019.
He also served as the Vice President-Investor Relations at MediGene AG.
Prior to that, he was a Research Analyst at Nomura Code Securities Ltd.
from 2005 to 2013.
He also worked as a Principal at KBC Peel Hunt Ltd.
and as an Analyst at Zeus Capital Ltd.
(Broker) from 2014 to 2017.
Dr. Waanders holds a doctorate degree from Monash University and an MBA from the University of Durham.
Actieve functies van Gary Waanders
| Bedrijven | Functie | Begin |
|---|---|---|
| AC IMMUNE SA | Investor Relations Contact | - |
Eerdere bekende functies van Gary Waanders
| Bedrijven | Functie | Einde |
|---|---|---|
| MEDIGENE AG | Investor Relations Contact | 01-06-2021 |
Bryan, Garnier & Co Ltd.
 Bryan, Garnier & Co Ltd. Investment Banks/BrokersFinance Bryan, Garnier & Co Ltd. is a European, full-service growth-focused independent investment bank for technology, healthcare, consumer, and business services companies. The private company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company is well-positioned in a capex intensive industry that is increasingly dynamic both in capital raising and M & A, driven by the 4th Industrial Revolution. Bryan Garnier is the world's leading independent full-service investment bank for European healthcare and technology-led companies and their investors. The company is focused on new disruptive technologies and alternative production models in a variety of domains geared towards fighting climate change and environmental degradation. The consumer sector is transformed across its segments by the way digital natives relate to brands, products, and the environment. The company was founded in 1996 by Olivier Marie Paul Garnier de Falletans. | Analyst-Equity | 26-07-2019 |
| Zeus Capital Ltd. (Broker) | Analyst-Equity | 01-06-2017 |
| Nomura Code Securities Ltd. | Analyst-Equity | 01-09-2013 |
| KBC Peel Hunt Ltd. | Analyst-Equity | - |
Opleiding van Gary Waanders
| University of Durham | Masters Business Admin |
| Monash University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| MEDIGENE AG | Health Technology |
| AC IMMUNE SA | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
| Nomura Code Securities Ltd. | Finance |
| KBC Peel Hunt Ltd. | Finance |
| Zeus Capital Ltd. (Broker) | Finance |
Bryan, Garnier & Co Ltd.
Bryan, Garnier & Co Ltd. Investment Banks/BrokersFinance Bryan, Garnier & Co Ltd. is a European, full-service growth-focused independent investment bank for technology, healthcare, consumer, and business services companies. The private company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company is well-positioned in a capex intensive industry that is increasingly dynamic both in capital raising and M & A, driven by the 4th Industrial Revolution. Bryan Garnier is the world's leading independent full-service investment bank for European healthcare and technology-led companies and their investors. The company is focused on new disruptive technologies and alternative production models in a variety of domains geared towards fighting climate change and environmental degradation. The consumer sector is transformed across its segments by the way digital natives relate to brands, products, and the environment. The company was founded in 1996 by Olivier Marie Paul Garnier de Falletans. | Finance |
